- The prophylactic use of recombinant factor VIIa in a patient with DeBakey type III aortic dissection: A case report
-
Kim WJ, Oh JY, Son HJ, Chin JH, Choi DK, Lee EH, Sim JY, Choi IC
- KMID: 2092327
- Korean J Anesthesiol.
- 2011 Nov;61(5):431-434.
- doi: 10.4097/kjae.2011.61.5.431
Little is known about the prophylactic use of recombinant factor VIIa (rFVIIa) in patients undergoing surgery for a bleeding aorta employing cardiopulmonary bypass. We report the successful use of rFVIIa... -
- CITED
-
- Close
- SHARE
-
- Close
- Recombinant Factor VIIa Treatment for Acute Intracerebral Hemorrhage
-
Ahn JY, Joo JY
- KMID: 2029786
- Korean J Cerebrovasc Surg.
- 2006 Dec;8(4):273-278.
Intracerebral hemorrhage is a lethal stroke type with a high morbidity and mortality. Hematoma growth is one of the independent determinants of neurological and functional outcomes after intracerebral hemorrhage. Attenuation... -
- CITED
-
- Close
- SHARE
-
- Close
- Diffuse alveolar hemorrhage and recombinant factor VIIa treatment in pediatric patients
-
Park JA
- KMID: 2163053
- Korean J Pediatr.
- 2016 Mar;59(3):105-113.
- doi: 10.3345/kjp.2016.59.3.105
Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication in patients with hematologic malignancies or autoimmune disorders. The current treatment options, which include corticosteroids, transfusions, extracorporeal membrane oxygenation (ECMO), and... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Successful Endoscopic Submucosal Dissection of Gastric Adenoma in a Patient with Congenital Factor VII Deficiency
-
Kim SH, Choi SH, Lee JW, Shin WJ, Bang CS, Baik GH
- KMID: 2083686
- Korean J Helicobacter Up Gastrointest Res.
- 2015 Mar;15(1):49-52.
- doi: 10.7704/kjhugr.2015.15.1.49
Congenital factor VII deficiency is a rare hemorrhagic disorder, and invasive procedures are likely to cause excessive bleeding in these patients. Endoscopic submucosal dissection (ESD) has been accepted as a... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Desensitization for Hemophilia B Inhibitor Patient with Anaphylaxis to FIX Concentrates
-
Park Y, Yoo KY
- KMID: 2252186
- Korean J Hematol.
- 2008 Sep;43(3):179-183.
- doi: 10.5045/kjh.2008.43.3.179
Among the patients with hemophilia, 10~15% have hemophilia B, and 1~3% of the hemophilia B patients develop inhibitor to factor IX clotting activity. Allergic reactions to concentrates containing factor IX... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Successful Treatment of Childhood Intractable Gastrointestinal Hemorrhage with Low Dose Recombinant Activated Factor VII (NovoSeven (R))
-
Kim JY, Choe BH, Kwon S, Lee KS
- KMID: 2278326
- Korean J Pediatr Hematol Oncol.
- 2004 Oct;11(2):276-279.
Recombinant activated factor VII (rFVIIa, NovoSeven (R)) was initially developed for the treatment of bleeding in patients with hemophilia having antibodies against factor VIII or IX, and factor VII deficiency.... -
- CITED
-
- Close
- SHARE
-
- Close
- Orthognathic Surgery in a Patient with Factor VII Deficiency
-
Baek RM, Oh MJ, Lee SW
- KMID: 2203132
- J Korean Soc Plast Reconstr Surg.
- 2009 Jan;36(1):93-95.
PURPOSE: Congenital factor VII(FVII) deficiency is a rare bleeding disorder and surgery can cause excessive bleeding due to an extrinsic pathway problem. It can be diagnosed by increased PT and... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent Advance of Pharmacotherapy in Hemophilia
-
Park YS
- KMID: 2188133
- J Korean Med Assoc.
- 2009 Dec;52(12):1201-1206.
- doi: 10.5124/jkma.2009.52.12.1201
Hemophilia A (factor VIII deficiency) and Hemophilia B (factor IX deficiency) are the most common and serious congenital coagulation disorders. Accurate diagnosis is important and essential for effective management. A... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Glanzmann's Thrombasthenia Successfully Managed after Tonsillectomy
-
Choi JS, Jung GH, Lim JY, Kim YM, Kim SK
- KMID: 2279837
- Clin Pediatr Hematol Oncol.
- 2014 Apr;21(1):29-32.
Glanzmann's thrombasthenia (GT) is a rare autosomal recessive disease and platelet function disorder, in which platelet membrane GP IIb/ IIIa complex is defective and platelet aggregation is undeveloped. GT is... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Intractable Gastrointestinal Bleeding during Chemotherapy in Hereditary Coagulation Factor Deficiency
-
Lee JH, Lee KS
- KMID: 2279918
- Clin Pediatr Hematol Oncol.
- 2007 Oct;14(2):198-201.
A congenital factor VII deficiency is a rare bleeding disorder and autosomal recessively inherited. Its clinical manifestations are variable from asymptomatic to life threatening bleeding. Chemotherapy can cause a hemorrhagic... -
- CITED
-
- Close
- SHARE
-
- Close
- Introduction to Coagulation System
-
Lyu CJ
- KMID: 2188442
- J Korean Soc Neonatol.
- 2011 May;18(1):1-5.
- doi: 10.5385/jksn.2011.18.1.1
Coagulation involves the regulated sequence of proteolytic activation of a series of proteins to achieve appropriate and timely hemostasis in an injured vessel. In the non-pathological state, the inciting event... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Experience with Recombinant Activated Factor VII in a Surgical Patient with Coagulation Factor VII Deficiency: A case report
-
Kim SH, Lim KJ, Yoon SZ, Park KS, Do SH
- KMID: 2239885
- Korean J Anesthesiol.
- 2007 May;52(5):609-611.
- doi: 10.4097/kjae.2007.52.5.609
A 33-yr old female patient with coagulation factor VII deficiency was scheduled for laparoscopic oophorectomy under the diagnosis of ovarian teratoma. Plasma concentration of factor VII of this patient was... -
- CITED
-
- Close
- SHARE
-
- Close
- Post-operative Bleeding due to Acquired Hemophilia Successfully Treated with Recombinant Factor VIIa: Case Report
-
Lee N, Yoon SH, Lim W, Kim MH, Kim HJ, Kim SK, Park JS, Seol YM, Song MK, Choi YJ, Chung JS, Cho GJ
- KMID: 2252136
- Korean J Hematol.
- 2009 Sep;44(3):163-167.
- doi: 10.5045/kjh.2009.44.3.163
Acquired hemophilia is a rare but potentially life-threatening hemorrhagic disorder caused by the development of autoantibodies against coagulation factor VIII. Concentrates of human factor VIII, desmopressin, activated prothrombin complex concentrates,... -
- CITED
-
- Close
- SHARE
-
- Close
- Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience
-
Han MH, Park YS
- KMID: 2172876
- Blood Res.
- 2013 Dec;48(4):282-286.
- doi: 10.5045/br.2013.48.4.282
BACKGROUND: Currently, the greatest challenge in hemophilia treatment is managing hemophilia patients with inhibitors. The two main bypassing agents that are used to treat hemophilia patients with inhibitors are activated... -
- CITED
-
- Close
- SHARE
-
- Close
- Two Cases of Infant Hemophilia A Patients with Inhibitors
-
Yu DU, Park JK, Park YS
- KMID: 2084615
- Clin Pediatr Hematol Oncol.
- 2015 Oct;22(2):146-150.
- doi: 10.15264/cpho.2015.22.2.146
Development of inhibitors is currently one of the most serious complications of hemophilia treatment. Typically, the propensity to develop an inhibitor is likely influenced by both genetic and non-genetic factors.... -
- CITED
-
- Close
- SHARE
-
- Close
- Successful Hemostasis by the use of Recombinant Factor VIIa in Uncontrolled Active Hemorrhage of Multiple Trauma Patients
-
Joo YM, Yeom SR, Ryu JH, Jeong JW, Kim YI, Min MK, Park SW, Cho SJ
- KMID: 2332881
- J Korean Soc Emerg Med.
- 2011 Feb;22(1):22-29.
PURPOSE: Uncontrolled bleeding is a leading cause of death in multiple-injury patients. It is very difficult to control hemorrhage due to microvascular injury in soft tissue by surgery or vascular... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Efficacy of Recombinant Activated Factor VII in Management of Postpartum Hemorrhage
-
Moon SH, Kim SC, Joo JK, Suh DS, Lee DH
- KMID: 1427072
- Korean J Perinatol.
- 2013 Mar;24(1):29-36.
- doi: 10.14734/kjp.2013.24.1.29
PURPOSE: This study was aimed to investigate the clinical efficacy of recombinant activated factor VII (rFVIIa) for patients with intractable postpartum hemorrhage. METHODS: This was a retrospective study of ten patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Use of Recombinant Activated Factor VII for Pulmonary Hemorrhage in Premature Infants: A Single-Center Experience
-
Park HJ, Choi EJ
- KMID: 2168907
- Clin Pediatr Hematol Oncol.
- 2016 Apr;23(1):42-45.
- doi: 10.15264/cpho.2016.23.1.42
BACKGROUND: Pulmonary hemorrhage in prematurity is a life-threatening complication and associated with a high mortality. Recombinant activated factor VII (rFVIIa) has been reported as hemostatic treatment in sick neonates with... -
- CITED
-
- Close
- SHARE
-
- Close
- Recombinant Activated Factor VII as a Second Line Treatment for Postpartum Hemorrhage
-
Park SC, Yeom SR, Han SK, Jo YM, Kim HB
- KMID: 2405119
- Korean J Crit Care Med.
- 2017 Nov;32(4):333-339.
- doi: 10.4266/kjccm.2016.00787
BACKGROUND: Severe or massive postpartum hemorrhage (PPH) has remained a leading cause of maternal mortality for decades across the world and it results in critical obstetric complications. Recombinant activated factor... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of Recombinant Factor VIIa Treatment for Massive Hemorrhage in Patients with Multiple Traumas
-
Koh YR, Cho SJ, Yeom SR, Chang CL, Lee EY, Son HC, Kim HH
- KMID: 1245255
- Ann Lab Med.
- 2012 Mar;32(2):145-152.
- doi: 10.3343/alm.2012.32.2.145
BACKGROUND: Recent studies and case reports have shown that recombinant factor VIIa (rFVIIa) treatment is effective for reversing coagulopathy and reducing blood transfusion requirements in trauma patients with life-threatening hemorrhage.... -
- CITED
-
- Close
- SHARE
-
- Close
